Home > Quotes > PCYC > Press Releases
PCYC

Pharmacyclics, Inc. Press Releases

$84.89
*  
0.97
  negative  
1.16%
Get PCYC Alerts
*Delayed - data as of May 17, 2013 
Exchange: NASDAQ
Industry: Consumer Durables
Community Rating:
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored
Viewing
Filtered By
Ordered By

Pharmacyclics Reports First Quarter 2013 Results
05/01/2013 4:05PM - PR Newswire

Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
04/24/2013 4:05PM - PR Newswire

Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK
04/18/2013 4:05PM - PR Newswire

Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
04/11/2013 6:30AM - PR Newswire

Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
04/08/2013 1:00PM - PR Newswire

Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
04/08/2013 6:30AM - PR Newswire

Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
04/08/2013 6:30AM - PR Newswire

Pharmacyclics, Inc. Prices Public Offering of Common Stock
03/08/2013 8:18AM - PR Newswire

Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
03/07/2013 4:37PM - PR Newswire